Aliases & Classifications for Mouth Disease

MalaCards integrated aliases for Mouth Disease:

Name: Mouth Disease 12 15 17
Mouth Diseases 43 71
Mouth Disorders 42

Classifications:



External Ids:

Disease Ontology 12 DOID:403
MeSH 43 D009059
NCIt 49 C27641 C3240
UMLS 71 C0026636

Summaries for Mouth Disease

MedlinePlus : 42 Your mouth is one of the most important parts of your body. It has many different functions. It allows you to Take in food and drink Breathe in air Start digestion, with your teeth chewing the food you eat and your salivary glands releasing saliva to help break down the food Speak and sing Show emotion, by smiling or pouting Any problem that affects your mouth can make it hard to eat, drink, or even smile. Some common mouth problems include Cold sores - painful sores on the lips and around the mouth, caused by a virus Canker sores - painful sores in the mouth, caused by bacteria or viruses Thrush - a yeast infection that causes white patches in your mouth Leukoplakia - white patches of excess cell growth on the cheeks, gums or tongue, common in smokers Dry mouth - a lack of enough saliva, caused by some medicines and certain diseases Gum or tooth problems Bad breath Treatment for mouth disorders varies, depending on the problem. If a mouth problem is caused by some other disease, treating that disease can help. It is also important to keep your mouth clean and healthy by brushing, flossing, and not using tobacco.

MalaCards based summary : Mouth Disease, also known as mouth diseases, is related to hand, foot and mouth disease and stomatitis, and has symptoms including tinnitus, halitosis and snoring. An important gene associated with Mouth Disease is G3BP1 (G3BP Stress Granule Assembly Factor 1), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Mannitol and Ribavirin have been mentioned in the context of this disorder. Affiliated tissues include mouth, testes and kidney, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Disease Ontology : 12 A gastrointestinal system disease that is located in the mouth.

Related Diseases for Mouth Disease

Diseases related to Mouth Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 502)
# Related Disease Score Top Affiliating Genes
1 hand, foot and mouth disease 35.1 TLR7 TLR4 TLR3 SCARB2 IL6 IL13
2 stomatitis 32.1 TLR4 IL6 IL10 IFNG DDX58
3 exanthem 32.0 IL6 IL10 CRP
4 encephalitis 31.9 TLR3 IRF3 IL6 IL10 DDX58
5 herpangina 31.9 TP53 TLR7 TLR4 TLR3 IL6 IL10
6 myocarditis 31.9 TLR4 TLR3 IL6 IL10 IFNG
7 poliomyelitis 31.7 SCARB2 IL10 IFNG
8 pulmonary edema 31.6 IL13 IL10 CRP
9 dermatitis 31.4 TLR4 IL6 IL13 IL10 IFNG
10 viral infectious disease 31.4 TLR7 TLR4 TLR3 STAT1 IRF3 IL6
11 rhinitis 31.4 IL6 IL13 IL10 IFNG
12 vaccinia 31.4 TP53 STAT1 IRF3 IL6
13 brucellosis 31.4 TLR4 IL6 IL10 IFNG CRP
14 chickenpox 31.4 TLR3 STAT1 IL6 IL10 IFNG CRP
15 plague 31.3 TLR4 IL6 IL10 DDX58
16 meningitis 31.3 TLR4 IL6 IL10 IFNG CRP
17 allergic hypersensitivity disease 31.2 TLR4 IL13 IL10 IFNG
18 measles 31.2 TLR7 TLR4 TLR3 STAT1 IRF3 IL6
19 viral encephalitis 31.2 TLR3 IL6 IL10
20 meningoencephalitis 31.2 IL6 IL10 CRP
21 aphthous stomatitis 31.2 TLR4 IL6 IL10 IFNG
22 hepatitis a 31.1 TLR4 TLR3 IL10 IFNG
23 diarrhea 31.1 TLR4 IL6 IL10 IFNG
24 skin disease 31.0 VTN VDR TLR4 IL6 IL13 IL10
25 trypanosomiasis 31.0 TLR4 STAT1 IL6 IL10 IFNG
26 rabies 31.0 TLR3 STAT1 IRF3 DDX58
27 dermatitis, atopic 31.0 TLR7 TLR4 TLR3 STAT1 IL6 IL17F
28 chorioretinitis 30.9 IL6 IL10 IFNG
29 chlamydia 30.9 TLR4 IL6 IL10 IFNG CRP
30 endocarditis 30.9 IL6 IL10 IFNG CRP
31 acute pancreatitis 30.9 TLR4 IL6 IL10 CRP
32 tetanus 30.9 IL6 IL13 IL10 IFNG CRP
33 human immunodeficiency virus type 1 30.9 TLR3 STAT1 IRF3 IL6 IL10 IFNG
34 severe acute respiratory syndrome 30.8 STAT1 IRF3 IL6 IL10 IFNG DDX58
35 influenza 30.8 TLR7 TLR3 STAT1 IRF3 IL6 IFNG
36 immune deficiency disease 30.8 VDR STAT1 IL6 IL13 IL10 IFNG
37 herpes simplex 30.8 TLR3 STAT1 IRF3 DDX58
38 bronchopneumonia 30.7 TLR4 IL6 IL10 CRP
39 encephalomalacia 30.7 TLR4 IL6 CRP
40 neuroretinitis 30.7 IFNG CRP
41 appendicitis 30.7 TLR4 IL6 IL10 IFNG CRP
42 acute myocarditis 30.7 TLR3 STAT1 IL6 IL10 CRP
43 tonsillitis 30.7 TLR4 TLR3 IL6 IL10 IFNG
44 common cold 30.7 TLR4 TLR3 IL6 IL13 IL10
45 pericarditis 30.7 VTN IL6 IFNG CRP
46 peritonitis 30.7 TLR4 IL6 IL10 IFNG CRP
47 gastroenteritis 30.7 IL6 IL10 IFNG CRP
48 acquired immunodeficiency syndrome 30.7 TP53 IL6 IL10 IFNG CRP
49 conjunctivitis 30.7 TLR3 IL6 IL13 IL10 IFNG
50 perinatal necrotizing enterocolitis 30.7 TLR7 TLR4 TLR3 IL6 IL10 CRP

Graphical network of the top 20 diseases related to Mouth Disease:



Diseases related to Mouth Disease

Symptoms & Phenotypes for Mouth Disease

UMLS symptoms related to Mouth Disease:


tinnitus, halitosis, snoring, sore throat, coughing, vertigo/dizziness, equilibration disorder, oral manifestations

GenomeRNAi Phenotypes related to Mouth Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 9.44 CRP
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 9.44 IL10
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-22 9.44 TLR4
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 9.44 IL10
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-38 9.44 EIF4G1
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 9.44 IL10
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-65 9.44 IL10
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.44 CRP EIF4G1 IL10 TLR4
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-89 9.44 CRP
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-94 9.44 EIF4G1

MGI Mouse Phenotypes related to Mouth Disease:

45 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.43 DDX58 IFNG IL10 IL13 IL17F IL6
2 homeostasis/metabolism MP:0005376 10.41 CRP DDX58 IFNG IL10 IL13 IL6
3 immune system MP:0005387 10.4 CRP DDX58 IFNG IL10 IL13 IL17F
4 cellular MP:0005384 10.39 DDX58 G3BP1 IFNG IL10 IL13 IL6
5 cardiovascular system MP:0005385 10.36 CRP G3BP1 IFNG IL10 IL6 NOTCH1
6 growth/size/body region MP:0005378 10.36 DDX58 G3BP1 IFNG IL10 IL13 IL17F
7 mortality/aging MP:0010768 10.34 DDX58 G3BP1 G3BP2 IFNG IL10 IL13
8 digestive/alimentary MP:0005381 10.3 DDX58 IFNG IL10 IL13 IL17F IL6
9 integument MP:0010771 10.13 IFNG IL10 IL13 IL6 NOTCH1 STAT1
10 craniofacial MP:0005382 10.11 G3BP1 IFNG IL10 IL17F NOTCH1 TP53
11 muscle MP:0005369 10.1 IFNG IL10 IL13 IL6 NOTCH1 STAT1
12 nervous system MP:0003631 10.1 G3BP1 IFNG IL10 IL13 IL6 NOTCH1
13 liver/biliary system MP:0005370 10.06 DDX58 IFNG IL10 IL6 NOTCH1 STAT1
14 neoplasm MP:0002006 10.02 DDX58 IFNG IL10 IL6 NOTCH1 STAT1
15 hearing/vestibular/ear MP:0005377 10.01 IL13 NOTCH1 SCARB2 TLR4 TP53 VDR
16 normal MP:0002873 9.91 EIF4G1 IFNG IL10 IL17F NOTCH1 STAT1
17 renal/urinary system MP:0005367 9.76 IFNG IL6 NOTCH1 SCARB2 TLR4 TLR7
18 respiratory system MP:0005388 9.7 G3BP1 IFNG IL10 IL13 IL17F IL6
19 skeleton MP:0005390 9.36 IFNG IL10 IL13 IL17F IL6 NOTCH1

Drugs & Therapeutics for Mouth Disease

Drugs for Mouth Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 95)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
2
Ribavirin Approved Phase 4 36791-04-5 37542
3 Antiviral Agents Phase 4
4 Antimetabolites Phase 4
5 Antibodies, Blocking Phase 4
6 Immunoglobulins Phase 4
7 Antibodies Phase 4
8 Vaccines Phase 4
9 Immunologic Factors Phase 4
10 Anti-Infective Agents Phase 3
11 Anti-Infective Agents, Local Phase 3
12 Chlorhexidine gluconate Phase 3
13 Dermatologic Agents Phase 3
14 Disinfectants Phase 3
15
Ibuprofen Approved Phase 2 15687-27-1 3672
16
Acetaminophen Approved Phase 2 103-90-2 1983
17
Sucralfate Approved Phase 2 54182-58-0
18
Aluminum hydroxide Approved, Investigational Phase 2 21645-51-2
19
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 2 7487-88-9 24083
20
Nicotine Approved Phase 1, Phase 2 54-11-5 942 89594
21
Aluminum sulfate Approved Phase 2 10043-01-3
22
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 68-26-8, 11103-57-4, 22737-96-8 445354 9904001
23
Calcium Approved, Nutraceutical Phase 2 7440-70-2 271
24
Lobeline Investigational Phase 2 90-69-7
25 Anti-Inflammatory Agents Phase 2
26 Analgesics, Non-Narcotic Phase 2
27 Anti-Inflammatory Agents, Non-Steroidal Phase 2
28 Antipyretics Phase 2
29 Cyclooxygenase Inhibitors Phase 2
30 Antirheumatic Agents Phase 2
31 Gastrointestinal Agents Phase 2
32 Autonomic Agents Phase 2
33 Hormones Phase 2
34 Anti-Ulcer Agents Phase 2
35 Analgesics Phase 2
36 Antacids Phase 2
37 Central Nervous System Depressants Phase 2
38 Tocolytic Agents Phase 2
39 Anti-Arrhythmia Agents Phase 2
40 retinol Phase 2
41 Retinol palmitate Phase 2
42 Anesthetics Phase 2
43 Anticonvulsants Phase 2
44 calcium channel blockers Phase 2
45 Calcium, Dietary Phase 2
46 Neurotransmitter Agents Phase 2
47 Central Nervous System Stimulants Phase 2
48 Nicotinic Agonists Phase 2
49 Cholinergic Agents Phase 2
50 Respiratory System Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 85)
# Name Status NCT ID Phase Drugs
1 Safety, Three Batches Consistency and Immunity Duration of the Post-marketing Inactivated Enterovirus Type 71 (EV71) Vaccine in Children Aged 6-71 Months Unknown status NCT02889497 Phase 4
2 The Safety and Immunogenicity of Enterovirus Type 71 Inactivated Vaccine (Human Diploid Cell) With Two Measles Attenuated Live Vaccine and Live Attenuated Japanese Encephalitis Vaccine at the Same Time Point in Infants (8-month-old) Unknown status NCT03296410 Phase 4
3 Effect and Safety of Xiao'er Jiebiao Oral Liquid in Combination With Standard Treatment on Hand-foot-mouth Disease in Pediatric Patients Completed NCT02328651 Phase 4 Ribavirin plus Xiao'er jiebiao oral liquid;Ribavirin
4 A Phase IV Open-labelled, Single-centered, Stratified-randomized Clinical Trial in Zhejiang Province to Evaluate the Safety and Immunogenicity of EV71 Vaccine Developed by Sinovac Biotech Co., Ltd. Completed NCT03278132 Phase 4
5 A Opened,Randomized and Controlled Trial to Evaluate the Immunity and Safety of Sequential Vaccination of Two Different Commercial EV71 Inactived Vaccines in Healthy Infants Aged 6-35 Months Completed NCT03873740 Phase 4
6 A Randomized, Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Recombinant Hepatitis B Vaccine/Group A Meningococcal Polysaccharide Vaccine Completed NCT03274102 Phase 4
7 Effectiveness and Safety of Inactivated EV71 Vaccine (Human Diploid Cell) in 6-71 Months Children: an Open-label Controlled Phase Ⅳ Clinical Study Completed NCT03001986 Phase 4
8 Peri-implantitis - Regenerative Treatment With Enamel Matrix Derivative (EMD). Clinical Effects, Microbial Profiles and Molecular Mechanisms. A Randomised Controlled Pilot Study. Completed NCT02500654 Phase 4
9 Multiple Centers, Randomized, and Control Trail on the Immunogenicity and Safety of the Simultaneously Vaccination of Inactivated Enterovirus 71 Vaccine (EV71) and Seasonal Influenza Vaccine(SIV) Recruiting NCT04133584 Phase 4
10 A Randomized, Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Measles, Mumps, and Rubella Combined Live Attenuated Vaccine/ Encephalitis Live Attenuated Vaccine Recruiting NCT04111432 Phase 4
11 Study on Immunogenicity of Inactivated Enterovirus 71 (EV71) Vaccine (Human Diploid Cell, KMB-17) in Large-scale Healthy Children in China Active, not recruiting NCT03240744 Phase 4
12 Phase Ⅳ Clinical Trial, to Evaluate the Efficacy of the Enterovirus 71 (EV71) Inactivated Vaccine and Its Correlation With EV71 Antibody Level Active, not recruiting NCT03903926 Phase 4
13 The Safety, Immune Persistence and Consistency of Inactivated Enterovirus 71 Vaccine (Human Diploid Cell, KMB-17) Active, not recruiting NCT02999828 Phase 4
14 A Phase IV Clinical Trial for Efficacy Evaluation for Inactivated Vaccine (Vero Cell) Against EV71: A Multicenter, Case-control Study. Enrolling by invitation NCT03582761 Phase 4
15 Three Batches Consistency, Immunity Duration and Safety of Inactivated Enterovirus 71 Vaccine Post-marketing Among Children Aged 6-35 Months in China Not yet recruiting NCT03893747 Phase 4
16 A Multicentered, Double - Blind, Randomized, and Placebo - Controlled Clinical Trial With Inactivated Enterovirus Type 71 (EV71) Vaccines Completed NCT01507857 Phase 3
17 A Multiple-center Randomized Double-blind Placebo-controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of an Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children Aged 6-35 Months Completed NCT01508247 Phase 3
18 Immunogenicity and Safety of Three Consecutive Lots of a New Inactivated Enterovirus Type 71 (EV71) Vaccine: A Double-blind, Randomized and Controlled Trial Completed NCT01636245 Phase 3
19 Multi-Center Phase 3 Trial of Chlorhexidine Gluconate Chip for the Use in Subjects With Peri-Implantitis. Completed NCT02080403 Phase 3 2.5 mg Chlorhexidine gluconate chip
20 A Phase III Clinical Trial for Inactivated Enterovirus Type 71 Vaccine (Human Diploid Cell, KMB-17 Cell) in Chinese Infants and Children Completed NCT01569581 Phase 3
21 A Phase III Clinical Trial With Randomized, Double-blinded, Controlled Design as Well as Bridging Design to Evaluate the Safety and Immunogenicity of EV71 Vaccine in Children Aged 36-71 Months Active, not recruiting NCT03909074 Phase 3
22 Sucralfate to Improve Oral Intake in Children With Infectious Oral Ulcers: a Randomized, Double-blind, Placebo-Controlled Trial Unknown status NCT03241030 Phase 2 Sucralfate;Acetaminophen;Ibuprofen
23 An Open-Label, Dose-Finding, Phase II Study to Evaluate the Immunogenicity and Safety of the Bioreactor-generated EV71 Vaccine in Pediatric Subjects Aged 3 to 6 Years and 2 to 35 Months Old Unknown status NCT03268083 Phase 2
24 A Phase 2b, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Three Different Doses of SCV 07 in Attenuating Oral Mucositis in Subjects With Head and Neck Cancer Receiving Concurrent Chemotherapy and Radiotherapy Unknown status NCT01247246 Phase 2 SCV-07;Placebo
25 Periapical Bone Healing After Apicectomy With and Without Retrograde Root Filling Unknown status NCT00228280 Phase 1, Phase 2
26 A Phase II Clinical Trial for Inactivated Enterovirus Type 71 Vaccine (Human Diploid Cell, KMB-17 Cell) in Chinese Infants Completed NCT01512706 Phase 2
27 A Randomized, Placebo-controlled, Double-blind Trial of Intravenous Magnesium Sulfate for the Management of Severe Hand, Foot and Mouth Disease With Autonomic Nervous System Dysregulation in Vietnamese Children. Completed NCT01940250 Phase 2 Magnesium Sulphate;Sterile water
28 Phase II, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of the Effects of RK-0202 on Oral Mucositis in Patients Receiving Radiation Therapy for Tumors of the Oral Cavity, Oropharynx, Nasopharynx, Salivary Glands or Supraglottic Region Completed NCT00230191 Phase 2 RK-0202
29 A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of CG53135-05 Administered Intravenously as a Single Dose for the Prevention of Oral Mucositis in Patients Receiving Autologous Hematopoietic Stem Cell Transplant Completed NCT00104065 Phase 2 CG53135-05, velafermin
30 A Phase II Randomized Double Blind Placebo Controlled Trial to Assess Safety and Efficacy of Velafermin for Prevention of Oral Mucositis in Hematologic Cancer Patients Receiving Autologous Stem Cell Transplant Completed NCT00323518 Phase 2 velafermin;placebo
31 An Open-label, Dose-finding, Phase II Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine in Pediatric Subjects Aged 3 to 6 Years and 6 to 35 Months Old Completed NCT02777411 Phase 2
32 A Phase II Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants Completed NCT01399853 Phase 2
33 Evaluation of the Clinical Effects of Tooth Powder on Plaque Induced Gingivitis Completed NCT01902095 Phase 2
34 Treatment of Smokeless Tobacco Users Completed NCT00218270 Phase 2 Tobacco free snuff
35 Treatment of Smokeless Tobacco Users: Use of Nicotine Replacement Products to Reduce Smokeless Tobacco Use Completed NCT00218244 Phase 1, Phase 2
36 A Booster Dose of Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children Completed NCT01734408 Phase 2
37 An Adaptive Phase 2 Randomized Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Multiple LOU064 Doses in Patients With Moderate to Severe Sjögren's Syndrome (LOUiSSe) Recruiting NCT04035668 Phase 2 LOU064;Placebo
38 Intraoral Grafting of Ex Vivo Produced Oral Mucosal Composites Unknown status NCT00000111 Phase 1
39 Phase I, Double Blind, Randomized, Placebo-controlled, Dose Escalation Study to Assess the Safety and Immunogenicity of a Prophylactic Vaccine Against Enterovirus Infection in Healthy Adults Completed NCT01376479 Phase 1
40 A Phase Ia Clinical Trial for Inactivated Vaccine(Vero Cell) Against EV71 in Chinese Healthy Young Adults and Children Completed NCT01267903 Phase 1
41 A Blind, Randomized and Placebo-controlled Clinical Trial With Inactivated Enterovirus Type 71 Vaccines in Healthy Children. Completed NCT01273246 Phase 1
42 A Phase Ib Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants Completed NCT01313715 Phase 1
43 A Phase I Clinical Trial for Inactivated Enterovirus Type 71 Vaccine (Human Diploid Cell, KMB-17 Cell) in Chinese Adults, Children and Infants Completed NCT01391494 Phase 1
44 Evaluation of Polarized Reflectance Spectroscopy for Detection of High-risk Oral Lesions Completed NCT01604759 Phase 1
45 A Randomized, Double-blind, Placebo-controlled, Phase 1 Clinical Trial to Investigate the Safety and Immunogenicity of CJ-40010 After Administration in Healthy Subjects Recruiting NCT04182932 Phase 1
46 A Randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalation Study to Evaluate the Tolerance and Pharmacokinetics of Suramin Sodium in Healthy Chinese Adults Recruiting NCT03804749 Phase 1 suramin sodium
47 Validation and Dosimetry Study of [18F]-FBA-A20FMDV2 PET Ligand for Alpha(V)beta6 in Healthy Subjects and in the Lungs of Idiopathic Pulmonary Fibrosis (IPF) Subjects (PETAL Study) Terminated NCT02052297 Phase 1
48 A Multi-Center Clinical Trial To Evaluate Chinese Herbal Medicines in the Treatment of Severe Hand-foot-mouth Disease Unknown status NCT01145664 Herbal concentrate-granules plus western therapy;Reduning Injection plus western therapy;Western therapy
49 A Clinical Trial to Evaluate the Effectiveness and Safety of Xiyanping Injection in the Treatment of Mild Type of Hand, Foot, and Mouth Disease Unknown status NCT01182025 Xiyanping Injection;Xiyanping Injection with western medicine
50 A Clinical Trial To Evaluate Reduning Injection in the Treatment of Mild Type of Hand, Foot, and Mouth Disease Unknown status NCT01175915

Search NIH Clinical Center for Mouth Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Lidocaine
LIDOCAINE HCL PWDR
Lidocaine Hydrochloride
LIDOCAINE PWDR

Cochrane evidence based reviews: mouth diseases

Genetic Tests for Mouth Disease

Anatomical Context for Mouth Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Mouth Disease:

19
Mouth

MalaCards organs/tissues related to Mouth Disease:

40
Testes, Kidney, T Cells, Tongue, Skin, B Cells, Salivary Gland

Publications for Mouth Disease

Articles related to Mouth Disease:

(show top 50) (show all 9383)
# Title Authors PMID Year
1
Clinical Outline of Oral Diseases. 42
31735220 2020
2
Mucocutaneous Diseases. 42
31735224 2020
3
Oral Potentially Malignant Disorders. 42
31735231 2020
4
Exosomes cloak the virion to transmit Enterovirus 71 non-lytically. 61
31885311 2020
5
NLRP3 inflammasome activation by Foot-and-mouth disease virus infection mainly induced by viral RNA and non-structural protein 2B. 61
31840571 2020
6
Differential antibody responses to the major antigenic sites of FMD virus serotype O after primo-vaccination, multiply-vaccination and after natural exposure. 61
31706082 2020
7
Association of polymorphisms in the vitamin D receptor gene with susceptibility to and severity of hand, foot, and mouth disease caused by coxsackievirus A16. 61
31587312 2020
8
The spatial heterogeneity of the associations between relative humidity and pediatric hand, foot and mouth disease: Evidence from a nation-wide multicity study from mainland China. 61
31874401 2020
9
First isolation of foot and mouth disease virus from wild boars in the Middle East. 61
32034998 2020
10
Foot-and-mouth disease outbreaks in captive scimitar-horned oryx (Oryx dammah). 61
32011088 2020
11
Inactivation of foot-and-mouth disease virus A/IRN/8/2015 with commercially available lysis buffers. 61
32035122 2020
12
The first full genome characterization of an Iranian Foot and mouth disease virus. 61
32023478 2020
13
The impact of changing farm structure on foot-and-mouth disease spread and control: A simulation study. 61
32012445 2020
14
Enhanced Efficacy of Immunization with a Foot-and-Mouth Disease Multi-Epitope Subunit Vaccine Using Mannan-Decorated Inulin Microparticles. 61
32002844 2020
15
Cell culture propagation of foot-and-mouth disease virus: adaptive amino acid substitutions in structural proteins and their functional implications. 61
31776851 2020
16
Effects of regional differences and demography in modelling foot-and-mouth disease in cattle at the national scale. 61
31897292 2020
17
Engineering viable foot-and-mouth disease viruses with increased acid stability facilitate the development of improved vaccines. 61
31900553 2020
18
Data on prevalence, distribution and risk factors for Foot and Mouth Disease in grazing cattle in haor areas of Bangladesh. 61
31956666 2020
19
Inactivation of foot-and-mouth disease virus in epithelium samples for safe transport and processing in low-containment laboratories. 61
31705919 2020
20
The interference effect of maternally-derived antibodies on the serological performance of pigs immunized with a foot-and-mouth disease oil emulsion vaccine. 61
31892447 2020
21
Substitution 3A protein of foot-and-mouth disease virus of attenuated ZB strain rescued the viral replication and infection in bovine cells. 61
31791012 2020
22
Negatively charged amino acids at the foot-and-mouth disease virus capsid reduce the virion-destabilizing effect of viral RNA at acidic pH. 61
32015411 2020
23
Immunogenicity of imported foot-and-mouth vaccines in different species in Mongolia. 61
31926753 2020
24
Crystallization of SLA-2*04:02:02 complexed with a CTL epitope derived from FMDV. 61
31760318 2020
25
Estimating viral bottleneck sizes for FMDV transmission within and between hosts and implications for the rate of viral evolution. 61
31897294 2020
26
FMD vaccine matching: Inter laboratory study for improved understanding of r1 values. 61
31765721 2020
27
Genetic characterization of VP1 of coxsackieviruses A2, A4, and A10 associated with hand, foot, and mouth disease in Vietnam in 2012-2017: endemic circulation and emergence of new HFMD-causing lineages. 61
32008121 2020
28
Non-polio enteroviruses among healthy children in the Philippines. 61
32013921 2020
29
Reversible Cerebral Angiopathy after Viral Infection in a Pediatric Patient with Genetic Variant of RNF213. 61
31818681 2020
30
Effectiveness of enterovirus A71 vaccine in severe hand, foot, and mouth disease cases in Guangxi, China. 61
31892446 2020
31
Neutralizing Antibodies against Enteroviruses in Patients with Hand, Foot and Mouth Disease. 61
31961293 2020
32
Hand-foot-and-mouth disease in uruguay: Coxsackievirus A6 identified as causative of an outbreak in a rural childcare center. 61
31502682 2020
33
Protective Immunity Elicited by VP1 Chimeric Antigens of Bacterial Ghosts against Hand-Foot-and-Mouth Disease Virus. 61
32024212 2020
34
First detection of foot-and-mouth disease virus O/ME-SA/ Ind2001e sublineage in Jordan. 61
31549490 2020
35
High-Resolution Composition Analysis of an Inactivated Polyvalent Foot-and-Mouth Disease Vaccine. 61
31963122 2020
36
Utilizing milk from pooling facilities as a novel approach for foot-and-mouth disease surveillance. 61
31961008 2020
37
Development and evaluation of silver amplification immunochromatography kit for foot-and-mouth disease virus antigen detection. 61
31669454 2020
38
Genetic Determinants of Altered Virulence of Type O Foot-and-Mouth Disease Virus. 61
31915277 2020
39
Timeliness of vesicular disease notification system in Brazilian foot-and-mouth disease surveillance programme. 61
31965759 2020
40
FOOT-AND-MOUTH DISEASE IN EXPERIMENTALLY INFECTED MULE DEER (ODOCOILEUS HEMIONUS). 61
31329525 2020
41
Evaluating the utility of national-scale data to estimate the local risk of foot-and-mouth disease in endemic regions. 61
31408585 2020
42
Model of persistent foot-and-mouth disease virus infection in multilayered cells derived from bovine dorsal soft palate. 61
31419374 2020
43
Horizontal transmission of foot-and-mouth disease virus O/JPN/2010 among different animal species by direct contact. 61
31482692 2020
44
Comparison of chemical extraction methods for determination of 146S content in foot-and-mouth disease oil-adjuvanted vaccine. 61
31562676 2020
45
Ribosomal Protein L13 Promotes IRES-Driven Translation of Foot-and-Mouth Disease Virus in a Helicase DDX3-Dependent Manner. 61
31619563 2020
46
A Single Dose of Dendrimer B2T Peptide Vaccine Partially Protects Pigs against Foot-and-Mouth Disease Virus Infection. 61
31936706 2020
47
Characterization of SAT2 foot-and-mouth disease 2013/2014 outbreak viruses at the wildlife-livestock interface in South Africa. 61
31984622 2020
48
A bivalent B-cell epitope dendrimer peptide can confer long lasting immunity in swine against foot-and-mouth disease. 61
31994334 2020
49
Foot-and-Mouth Disease Virus Serotype O/CATHAY Genome Sequences from Five Outbreaks in Vietnam, 2017 to 2019. 61
32001559 2020
50
Immunogenicity and protective efficacy of 3A truncated negative marker foot-and-mouth disease virus serotype A vaccine. 61
32002597 2020

Variations for Mouth Disease

Expression for Mouth Disease

Search GEO for disease gene expression data for Mouth Disease.

Pathways for Mouth Disease

Pathways related to Mouth Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.95 VTN TP53 TLR7 TLR4 TLR3 STAT1
2
Show member pathways
13.45 TP53 TLR7 TLR4 TLR3 STAT1 IL6
3
Show member pathways
13.36 TP53 STAT1 IRF3 IL6 IL17F IL13
4
Show member pathways
12.99 VTN TP53 TLR4 TLR3 STAT1 NOTCH1
5
Show member pathways
12.97 TP53 TLR4 TLR3 STAT1 IRF3 IL6
6
Show member pathways
12.96 TP53 TLR7 TLR4 TLR3 STAT1 IRF3
7 12.88 TP53 STAT1 NOTCH1 IL6 IL13 IFNG
8
Show member pathways
12.88 STAT1 IL6 IL13 IL10 IFNG EIF4G1
9 12.81 TP53 TLR3 STAT1 IRF3 IL6 IFNG
10
Show member pathways
12.79 TLR4 TLR3 IRF3 IL6 IFNG DDX58
11
Show member pathways
12.64 TLR4 STAT1 IL6 IL10 IFNG
12
Show member pathways
12.61 TP53 STAT1 IL6 IL17F IL10 IFNG
13
Show member pathways
12.58 STAT1 IRF3 IFNG EIF4G1 DDX58
14 12.52 TLR7 TLR3 STAT1 IRF3 IL10 IFNG
15
Show member pathways
12.52 TP53 TLR7 TLR4 TLR3 STAT1 IRF3
16
Show member pathways
12.46 VTN TLR7 TLR4 TLR3 IRF3
17
Show member pathways
12.4 TLR4 STAT1 NOTCH1 IL6 IL17F IL13
18
Show member pathways
12.37 STAT1 IL6 IL13 IL10 IFNG
19
Show member pathways
12.36 IL6 IL17F IL13 IFNG
20
Show member pathways
12.35 TP53 IL6 IFNG CRP
21
Show member pathways
12.29 TLR4 STAT1 IL10 IFNG
22
Show member pathways
12.29 TLR7 TLR4 TLR3 IRF3 IL6
23
Show member pathways
12.28 TP53 STAT1 IRF3 IL6 IL13 IL10
24 12.27 TLR4 STAT1 IRF3 IL6
25
Show member pathways
12.27 TP53 TLR4 TLR3 STAT1 IRF3 IL6
26
Show member pathways
12.25 TLR4 TLR3 STAT1 IFNG
27 12.23 VDR TLR4 STAT1 IL6 IL10 IFNG
28
Show member pathways
12.21 TLR7 TLR4 STAT1 IL6 IFNG
29
Show member pathways
12.08 TLR4 IL6 IL13 IFNG
30 12.06 TLR4 IRF3 IL6 IL10
31 12.05 TP53 TLR4 IL6 IFNG
32 12.03 NOTCH1 IL6 IL10 IFNG
33 11.98 VTN TP53 IL6 IFNG
34
Show member pathways
11.97 TP53 TLR7 TLR4 TLR3 STAT1 IL13
35 11.96 TLR4 IL6 IL10 IFNG
36 11.94 STAT1 IL6 IL10 IFNG
37 11.9 TP53 STAT1 IL6 IL17F IL13 IL10
38 11.87 VTN TLR7 TLR4 TLR3
39 11.82 TP53 STAT1 IL6 IL13 IFNG
40 11.81 TLR4 IRF3 IL6 IL10
41 11.8 TLR4 IL6 IFNG
42 11.8 IL13 IL10 IFNG
43 11.8 VTN TLR4 SCARB2 NOTCH1
44 11.79 TLR7 IL6 IL10 IFNG
45 11.76 IL6 IL13 IL10 IFNG
46 11.72 TP53 TLR7 TLR4 TLR3 STAT1 IL6
47 11.59 TP53 IL6 IFNG
48 11.58 TLR4 IL6 IL10 IFNG
49 11.57 IL6 IL13 IL10
50 11.53 VDR IL6 IFNG

GO Terms for Mouth Disease

Cellular components related to Mouth Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endosome membrane GO:0010008 9.26 TLR7 TLR4 TLR3 SCARB2
2 receptor complex GO:0043235 8.92 VDR TLR7 TLR4 NOTCH1

Biological processes related to Mouth Disease according to GeneCards Suite gene sharing:

(show all 50)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription by RNA polymerase II GO:0000122 10.18 VDR TP53 STAT1 NOTCH1 IRF3 IFNG
2 immune system process GO:0002376 10.15 TLR7 TLR4 TLR3 IRF3 G3BP1 DDX58
3 positive regulation of transcription, DNA-templated GO:0045893 10.14 TP53 STAT1 NOTCH1 IRF3 IL6 IL10
4 negative regulation of cell proliferation GO:0008285 10.09 VDR TP53 NOTCH1 IL6 IL10
5 innate immune response GO:0045087 10.08 TLR7 TLR4 TLR3 IRF3 G3BP2 G3BP1
6 immune response GO:0006955 10.06 VTN TLR7 TLR4 NOTCH1 IL6 IL13
7 cytokine-mediated signaling pathway GO:0019221 10.03 TP53 STAT1 IL6 IL17F IL13 IL10
8 viral process GO:0016032 10.01 TP53 STAT1 SCARB2 IRF3 G3BP2 G3BP1
9 cellular response to lipopolysaccharide GO:0071222 9.99 VDR TLR4 IRF3 IL6 IL10
10 response to lipopolysaccharide GO:0032496 9.97 TLR4 NOTCH1 IRF3 IL13 IL10
11 cellular response to mechanical stimulus GO:0071260 9.92 TLR7 TLR4 TLR3 IL13
12 inflammatory response GO:0006954 9.92 TLR7 TLR4 TLR3 IL6 IL17F IL13
13 interferon-gamma-mediated signaling pathway GO:0060333 9.9 TP53 STAT1 IRF3 IFNG
14 positive regulation of transcription by RNA polymerase II GO:0045944 9.9 VDR TP53 TLR4 TLR3 STAT1 NOTCH1
15 Ras protein signal transduction GO:0007265 9.88 TP53 G3BP2 G3BP1
16 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.88 IL6 IL13 IFNG
17 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.87 TLR7 TLR4 TLR3
18 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.87 TLR7 TLR4 TLR3
19 positive regulation of smooth muscle cell proliferation GO:0048661 9.86 STAT1 IL6 IL13
20 humoral immune response GO:0006959 9.85 NOTCH1 IL6 IFNG
21 toll-like receptor signaling pathway GO:0002224 9.84 TLR7 TLR4 TLR3
22 positive regulation of interleukin-6 secretion GO:2000778 9.83 TLR4 IL17F DDX58
23 response to exogenous dsRNA GO:0043330 9.83 TLR3 IRF3 DDX58
24 microglial cell activation GO:0001774 9.83 TLR7 TLR3 IL13 IFNG
25 positive regulation of JAK-STAT cascade GO:0046427 9.82 NOTCH1 IL6 IL10
26 TRIF-dependent toll-like receptor signaling pathway GO:0035666 9.82 TLR4 TLR3 IRF3
27 positive regulation of interleukin-12 production GO:0032735 9.81 TLR4 TLR3 IFNG
28 positive regulation of interleukin-8 production GO:0032757 9.81 TLR7 TLR4 TLR3 DDX58
29 necroptotic process GO:0070266 9.8 TP53 TLR4 TLR3
30 positive regulation of interferon-beta production GO:0032728 9.8 TLR4 TLR3 IRF3 DDX58
31 cellular response to exogenous dsRNA GO:0071360 9.79 TLR3 IRF3 DDX58
32 positive regulation of macrophage activation GO:0043032 9.78 TLR4 IL13 IL10
33 positive regulation of interleukin-6 production GO:0032755 9.77 TLR7 TLR4 TLR3 IL6 DDX58
34 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.76 TLR4 STAT1 IFNG
35 I-kappaB phosphorylation GO:0007252 9.74 TLR7 TLR4 TLR3
36 positive regulation of chemokine production GO:0032722 9.73 TLR7 TLR4 TLR3 IL6
37 positive regulation of MHC class II biosynthetic process GO:0045348 9.72 TLR4 IL10 IFNG
38 positive regulation of chemokine biosynthetic process GO:0045080 9.71 TLR3 IFNG
39 positive regulation of interferon-beta biosynthetic process GO:0045359 9.71 TLR7 TLR4 TLR3
40 negative regulation of lipid storage GO:0010888 9.7 IL6 CRP
41 negative regulation of MyD88-independent toll-like receptor signaling pathway GO:0034128 9.68 TLR4 TLR3
42 cytoplasmic sequestering of NF-kappaB GO:0007253 9.68 IL10 G3BP2
43 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.68 TP53 NOTCH1
44 detection of virus GO:0009597 9.67 TLR3 DDX58
45 positive regulation of interferon-alpha biosynthetic process GO:0045356 9.66 TLR7 TLR3
46 positive regulation of stress granule assembly GO:0062029 9.63 G3BP2 G3BP1
47 regulation of dendritic cell cytokine production GO:0002730 9.63 TLR4 TLR3
48 positive regulation of interferon-alpha production GO:0032727 9.56 TLR4 STAT1 IRF3 DDX58
49 defense response to virus GO:0051607 9.56 TLR7 TLR3 STAT1 IRF3 IL6 IFNG
50 positive regulation of gene expression GO:0010628 9.32 VDR TP53 TLR4 TLR3 NOTCH1 IL6

Molecular functions related to Mouth Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.86 TP53 TLR4 TLR3 STAT1 IRF3 EIF4G1
2 signaling receptor activity GO:0038023 9.67 VDR TLR4 TLR3 NOTCH1
3 protein binding GO:0005515 9.62 VTN VDR TP53 TLR7 TLR4 TLR3
4 cytokine activity GO:0005125 9.55 IL6 IL17F IL13 IL10 IFNG
5 double-stranded RNA binding GO:0003725 9.5 TLR7 TLR3 DDX58
6 transmembrane signaling receptor activity GO:0004888 9.35 TLR7 TLR4 TLR3 SCARB2 NOTCH1

Sources for Mouth Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....